The anticancer effects a new benzimidazole on HCC1937 breast cancer cell line

Abstract

Author(s): Lamia F. Abu-Marzoq*

Background: The lack of selectivity of the present medications and the decreased sensitivity to tumor therapies are the two main barriers to the treatment of solid tumors. This study's goal was to evaluate the anticancer activity of newly created benzimidazole medication compounds against the HCC1937 cell line, which has been the subject of numerous studies suggesting benzimidazole compounds and their derivatives as prospective targeted treatments and EGFR inhibitors.

Methods: Clonogenic survival assay used to inhibit the colony formation, A trypan blue assay was used to determine BA586's capacity to cause cell death in the HCC1937 cell line. MTT was used to assess the cytotoxicity of BA586 on HCC1937 triple-negative cells. To evaluate the BA586's capacity to prevent migration, a scratch motility assay was employed. The western blotting technique was performed to quantify the presence of several cell cycle arrest and apoptotic markers, which was also used to understand how the BA586 chemical works.

Results: With IC50 values of 42 M, our research showed that BA586 had a potent cytotoxic effect against HCC1937 cells in an amount-and time-dependent manner when applied in vitro. According to a trypan blue dye exclusion assay, the BA586 chemical significantly increases cell mortality in the HCC1937 cell line. The BA586 chemical significantly lowered the HCC1937 More than 68% of cells survive at 1000 cell concentrations, while 60% do so at 500 cell concentrations, according to clonogenic and mammosphere investigations. Western blotting analysis revealed that elevating the concentrations of p53 and p21 in treated cells, the chemical BA586 induces cell cycle arrest. Importantly, this chemical greatly (by more than 70%) inhibited the migration of the HCC1937 cell line. The findings also demonstrate that BA586 can cause DNA fragmentation, which increases p53 levels.

Conclusions: The newly discovered BA586 benzimidazole compound may be an effective anticancer agent against the HCC1937 cell line. 

Share this article